PRESS RELEASE published on 03/10/2026 at 09:00, 14 days 10 hours ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics réalise une levée de fonds de près de 1,7 million d'euros pour développer des thérapies géniques innovantes. Annonce de succès pour l'opération Biopharmaceutique Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
BRIEF published on 03/09/2026 at 07:35, 15 days 11 hours ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 15 days 11 hours ago GenSight Biologics fait le point sur ses programmes d'accès précoce et l'étude REVISE GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ® Étude REVISER Programmes D'accès Anticipé
BRIEF published on 03/09/2026 at 07:35, 15 days 11 hours ago GenSight Biologics : Point sur les Programmes d'Accès Précoce et l'Étude REVISE Thérapie Génique GenSight Biologics Neuropathie Optique Étude REVISE Accès Précoce
BRIEF published on 03/09/2026 at 07:35, 15 days 11 hours ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 15 days 12 hours ago Informations privilégiées / Autres communiqués GenSight Biologics fait le point sur les programmes d'accès précoce de GS010/LUMEVOQ et sur l'étude REVISE en cours, avec des approbations en France, Israël et aux États-Unis Thérapie Génique GenSight Biologics GS010/LUMEVOQ Accès Précoce Dose REVISE
PRESS RELEASE published on 03/09/2026 at 07:30, 15 days 12 hours ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 1 month 6 days ago GenSight Biologics renforce son leadership réglementaire grâce à des nominations clés Thérapie Génique GenSight Biologics Maladies De La Rétine Nominations Stratégiques Leadership Réglementaire
BRIEF published on 02/18/2026 at 07:35, 1 month 6 days ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
BRIEF published on 02/18/2026 at 07:35, 1 month 6 days ago GenSight Biologics Renforce son Équipe Réglementaire Affaires Réglementaires GenSight Biologics Thérapies Géniques Nominations Clés Essai Phase III
Published on 03/24/2026 at 18:55, 37 minutes ago Norse Gold Announces Closing of Private Placement Financing and Pending Reactivation on the TSX-V
Published on 03/24/2026 at 13:30, 6 hours 2 minutes ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 6 hours 2 minutes ago Innodata Announces Date of Annual Shareholder Meeting
Published on 03/24/2026 at 12:35, 6 hours 57 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 6 hours 59 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 19:05, 26 minutes ago WBS Power Advances 3.2 GW Energy Infrastructure for Hyperscale Data Center Campus
Published on 03/24/2026 at 18:39, 52 minutes ago EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026
Published on 03/24/2026 at 18:00, 1 hour 32 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 03/24/2026 at 17:50, 1 hour 42 minutes ago Annual General Meeting of Bellevue Group AG – all proposals approved
Published on 03/24/2026 at 17:46, 1 hour 45 minutes ago NRJ GROUP - Press release annual results 2025
